Vitruvian Partners LLP Maxcyte, Inc. Transaction History
Vitruvian Partners LLP
- $105 Million
- Q1 2025
A detailed history of Vitruvian Partners LLP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vitruvian Partners LLP holds 5,043,356 shares of MXCT stock, worth $10.8 Million. This represents 13.13% of its overall portfolio holdings.
Number of Shares
5,043,356
Previous 5,043,356
-0.0%
Holding current value
$10.8 Million
Previous $21 Million
34.38%
% of portfolio
13.13%
Previous 18.06%
Shares
3 transactions
Others Institutions Holding MXCT
# of Institutions
119Shares Held
73.2MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY10MShares$21.6 Million1.17% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$17.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY7MShares$15.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.57MShares$12 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X03.7MShares$7.96 Million0.43% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $219M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...